Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Global Penny Stocks To Watch In February 2025

In This Article:

Global markets have recently faced a turbulent period, with U.S. stocks experiencing declines amid geopolitical tensions and consumer spending concerns, while European indices displayed cautious optimism. Despite these market challenges, certain investment opportunities continue to attract attention, particularly in the realm of penny stocks. Although the term "penny stocks" might seem outdated, these typically smaller or newer companies offer unique growth potential when backed by strong financials and solid fundamentals. In this article, we spotlight several penny stocks that could stand out as hidden gems with promising prospects for investors seeking affordable entry points into the market.

Top 10 Penny Stocks Globally

Name

Share Price

Market Cap

Financial Health Rating

DXN Holdings Bhd (KLSE:DXN)

MYR0.515

MYR2.56B

★★★★★★

NEXG Berhad (KLSE:DSONIC)

MYR0.255

MYR709.45M

★★★★★★

Angler Gaming (NGM:ANGL)

SEK3.85

SEK288.69M

★★★★★★

T.A.C. Consumer (SET:TACC)

THB4.22

THB2.53B

★★★★★★

Foresight Group Holdings (LSE:FSG)

£3.85

£438.82M

★★★★★★

Hil Industries Berhad (KLSE:HIL)

MYR0.83

MYR275.51M

★★★★★★

Warpaint London (AIM:W7L)

£3.65

£294.87M

★★★★★★

Bosideng International Holdings (SEHK:3998)

HK$3.79

HK$44.89B

★★★★★★

Next 15 Group (AIM:NFG)

£3.03

£301.35M

★★★★☆☆

SKP Resources Bhd (KLSE:SKPRES)

MYR0.995

MYR1.55B

★★★★★☆

Click here to see the full list of 5,745 stocks from our Global Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Pacific Edge

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Pacific Edge Limited is a cancer diagnostics company that focuses on researching, developing, and commercializing tools for early cancer detection and management across New Zealand, the United States, and other international markets, with a market cap of NZ$51.15 million.

Operations: The company's revenue primarily comes from its Commercial segment, which generated NZ$22.57 million, complemented by NZ$3.78 million from Research activities.

Market Cap: NZ$51.15M

Pacific Edge Limited, with a market cap of NZ$51.15 million, focuses on cancer diagnostics and has generated revenue primarily from its Commercial segment (NZ$22.57 million) and Research activities (NZ$3.78 million). Despite being unprofitable with a negative return on equity (-70.8%), the company maintains more cash than debt and covers both short-term (NZ$8.4M) and long-term liabilities (NZ$1.8M) with short-term assets (NZ$44.3M). However, it faces high share price volatility and increased losses over five years at 14.7% annually, posing risks typical of penny stocks in the biotech sector.